Company intelligence / Profile preview

Syne Qua Non

Diss, Norfolk, United Kingdom

Ownership: Private
Development stage: Other

Overview

Syne Qua Non was a European specialist biometric CRO, excelling in trial data management, analytics, EDC, and ePRO services for clinical trials across biotech, pharma, and medical device sectors. They provided compliant, validated electronic capture systems and technology services for all trial phases, with a focus on patient-centric and technology-enabled data collection. The company is no longer active as an independent entity, having been acquired by Veristat, a global clinical services firm, in 2024.

Industry: Contract Research Organization

Beyond the preview

Go deeper on Syne Qua Non.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Syne Qua Non.

Explore the full profile